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Abstract
Background—Anemia is common in chronic kidney disease (CKD), and suboptimal management
of anemia can lead to serious health complications and poor quality of life.
Objectives—1) To describe health-related and overall quality of life among patients entering a
clinic focused on anemia management; 2) to compare their baseline quality of life with other relevant
populations; 3) to explore predictors of quality of life prior to anemia management; and 4) to explore
changes in quality of life over 1 year for patients managed in the clinic.
Methods—The Kidney Disease Quality of Life questionnaire – short form (KDQOL™-SF) was
used to measure kidney disease specific and overall quality of life in a cohort of pre-dialysis CKD
patients (n=79) enrolled in the clinic from January 2003 to September 2004. Baseline measures were
compared to previously published measurements. The influence of demographic and clinical
characteristics on baseline quality of life was explored. Changes in quality of life were evaluated
over time.
Results—Patients with CKD entering the clinic had lower overall quality of life compared with
estimates from the general US population (physical composite 35.7 vs. 48.4 and mental composite
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46.0 vs. 50.2, respectively). Clinic patients had better kidney disease specific scores than patients
with end stage kidney disease. General quality of life scores were similar regardless of kidney disease
severity, with the exception of physical functioning which was lowest for patients with end-stage
disease. Hemoglobin was the only factor predictive of quality of life. Over time, quality of life
improved among patients managed in the CKD clinic, with statistically significant improvements in
sleep (change of 6.2 ± 15.2; p < 0.05) and social function (change of 11.6 ± 27.7; p < 0.05).
Conclusions—Patients with anemia of chronic kidney disease reported reduced quality of life
compared to populations without kidney disease, but better quality of life compared to populations
with end stage kidney disease on dialysis. Quality of life generally improved among patients managed
in the multidisciplinary anemia clinic.
Keywords
Quality of life; chronic kidney disease; anemia; SF-36; KDQOL; multidisciplinary
BACKGROUND
Approximately 20 million people in the US have chronic kidney disease (CKD),1 and at least
eight million of these are classified as having moderate to severe disease (CKD Stages 3 through
5),2 which is defined by reduced kidney function measured by glomerular filtration rate (Table
1). Pre-dialysis CKD patients often exhibit many of the complications of end stage kidney
disease (ESRD), including metabolic bone disease, fluid and electrolyte disorders, and anemia.
Anemia complications generally are present after the glomerular filtration rate drops to less
than 60 ml/minute (i.e., ≥ stage 3), and the prevalence becomes greater as renal function is lost.
Inadequate management of anemia in patients on dialysis has been associated with negative
health outcomes, including left ventricular hypertrophy, decreased mental capacity,decreased
quality of life, and increased risk of hospitalizations.3–7 Some of these negative outcomes can
be avoided through administration of erythropoietic proteins (e.g., epoetin alfa or darbepoetin
alfa) and correction of anemia.8,9 Unfortunately, only one-third of CKD patients ever receive
treatment for anemia in the pre-dialysis time frame, as shown by publications reviewing clinical
characteristics of incident dialysis patients. 10 Furthermore, the average hematocrit at dialysis
initiation is approximately 30%, which is significantly less than that recommended by the
National Kidney Foundation.9,10 these data suggest that the effects of inadequate control of
anemia in the CKD population (pre-dialysis) requires additional study.
Reasons for inappropriate control of anemia may include such factors as high cost of
recombinant erythropoietins, failure of clinicians to screen for anemia in CKD, and lack of
integrated, multidisciplinary practice approaches. Integrated, multidisciplinary practice
approaches are particularly important in managing anemia, because related drug therapy
requires frequent assessments of hemoglobin levels, adjustments of doses/frequencies, and
adequate documentation to obtain insurance coverage.
We have previously described our Institution’s multidisciplinary approach to managing pre-
dialysis CKD-related anemia.11 Given the practicality and the improved clinical outcomes of
the multidisciplinary CKD clinic, we sought to explore health-related quality of life outcomes
for patients enrolled in the clinic. In light of recent controversies over hemoglobin targets and
potential cardiovascular adverse events with erythropoietic stimulating proteins, it is important
to note that at the time of this study our Institution had adapted hemoglobin targets consistent
with current recommendations.12,13 Thus, quality of life among patients managed in our
Institution’s multidisciplinary clinic is likely to be reflective of the current environment.
The objectives of this paper are as follows:
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1. to describe kidney disease-related and general health-related quality of life among
patients entering a clinic focused on anemia management;
2. to compare quality of life among our sample to estimates from the general US
population and previous studies of patients with varying degrees of kidney disease;
3. to explore whether certain demographic and clinical characteristics are predictive of
quality of life among patients beginning anemia management therapy; and
4. to explore changes in quality of life over 1 year for patients managed in the clinic.
To our knowledge, our study is the first to provide benchmark data for the kidney disease
specific scales using the Kidney Disease Quality of Life instrument – short form (KDQOL-
SF™, Rand Corporation, Santa Monica, CA).14 Further, our exploratory analyses provide
insights into important predictors of quality of life and the benefits of appropriate management
of anemia among patients with CKD.
METHODS
Study subjects and procedures
A study to collect clinical and quality of life outcomes in a CKD clinic was approved by the
University’s Committee on the Protection of the Rights of Human Subjects and conducted in
accordance with the Good Clinical Practice guidelines and the Declaration of Helsinki. Data
were collected from patients participating in the CKD clinic between January 2003 and
September 2004. The qualification for entry into the CKD clinic was the presence of anemia
requiring erythropoietic stimulating agents and not currently requiring renal replacement
therapy (i.e., pre-dialysis).11 The mean (SD) GFR for patients in this clinic was 29.3 (18.1)
mL/min, with most patients being classified as Stages 3 and 4 CKD. To be included in the
current study, patients had to have completed the KDQOL-SF™ at least once after entering
the clinic. Changes in the KDQOL-SF™ over time were assessed only for patients that returned
at 6 and/or 12 months.
Measures
The KDQOL-SF™ is a self report measure originally developed for individuals with kidney
disease and on dialysis.14 We excluded dialysis-specific questions because our patient
population did not have severe enough kidney disease to require dialysis.. This instrument
previously has been used in CKD,15, 16 although formal validation work has not been
conducted. Our analysis focused on 9 domains of health-related concerns of individuals with
kidney disease, including 1) symptoms/problems, 2) effects of kidney disease, 3) burden of
kidney disease, 4) work status, 5) cognitive function, 6) quality of social interaction, 7) sexual
function, 8) sleep, and 9) social support. The internal consistency reliability estimates 17 for
domains of the scale range from 0.61 to 0.90, while correlations with the KDQOL™ Long-
Form (criterion validity) range from 0.91 to 1.00.18 Numeric responses to the KDQOL-SF™
are pre-coded so that higher numbers reflect better health. Raw scores are then transformed to
a 0 to 100 scale, so that the lowest possible score is set at 0 and the highest score set at 100.
Items within each domain are averaged together to create a summary scale score. We chose
not to report an overall health score because our modified scale (deleting specific domains)
has not been previously validated.
The KDQOL-SF™ also includes a 36-item health survey (SF-36) 19, 20 which consists of 8
multi-item measures assessing 1) physical functioning, 2) role limitations caused by physical
health problems, 3) role limitations caused by emotional health problems, 4) social functioning,
5) emotional well-being, 6) pain, 7) energy/fatigue, and 8) general health perceptions. We
calculated overall physical and mental health status composites for this portion of the scale.
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Based on the Medical Outcomes Study, internal consistency reliability estimates were 0.78 or
greater for each domain of the SF-36,20 and multiple studies have supported its construct
validity.21, 22 Similar to the KDQOL-SF™ scales, SF-36 scale scores are transformed linearly
into a 0 to 100 point scale with higher values representing better health. We used the modified
RAND scoring algorithm to calculate scores.14, 20 The RAND algorithm is similar to the
Medical Outcomes Study algorithm with the exception of slightly higher pain scale scores for
the RAND algorithm.20
Statistical analysis
Patient demographic data and key laboratory data were abstracted and compared according to
whether they completed only a baseline KDQOL-SF™ or completed at least one follow-up
KDQOL-SF™. Differences in baseline characteristics for these groups were assessed using
Chi Square or Fisher’s Exact test for categorical data and unpaired T-test or the Mann Whitney
U test for continuous variables. After calculating means and standard deviations for individual
KDQOL-SF™ scale domains and composite scores, the group completing only a baseline
assessment was compared to the group that completed at least one follow-up assessment using
an unpaired T-test.
Baseline kidney disease specific scales and individual domains of the SF-36 from the study
CKD population and several reference populations were graphed and visually inspected to
evaluate similarity and differences among populations. US estimates from the Dialysis
Outcomes and Practice Patterns Study (DOPPS) 23 and a publication by Manns et al.24 were
used as benchmarks to compare kidney disease specific scales in patients with ESRD to our
population. In this comparison, the 9 scales reflect the same items included in the original
version of the KDQOL-SF™. Since we modified the instrument by deleting the dialysis staff
encouragement scale and the patient satisfaction scale, we do not report these values. General
health-related QOL (i.e., SF-36) in ESRD, pre-dialysis CKD, and the U.S. population were
compared to our CKD clinic patients. DOPPS 23 was used to compare quality of life in ESRD
to our CKD population. The Renal Research Institute-CKD Study 25 provided estimates of
health-related quality of life for 505 patients with CKD not requiring renal replacement therapy.
Finally, health-related quality of life estimates for the US population from the 1990 National
Survey of Functional Status (NSFHS) 26 were used.
As an exploratory analysis, multivariate analysis of variance (MANOVA) was used to evaluate
the impact of demographic and clinical characteristic variables on baseline assessment of 9
kidney disease specific domains of health-related concerns. Effects associated with a p-value
less than or equal to 0.05 were considered of interest. After obtaining a borderline significant
multivariate test for a hemoglobin effect, univariate ANOVA was conducted to identify the
specific domain that contributed to the significant overall effect.
Although our study was not statistically powered to assess changes over time, we explored
trends in QOL among patients who had at least one follow-up visit at which they completed a
QOL survey. Among these patients, some patients completed the KDQOL-SF™ assessment
at both 6 and 12 months (n=23) and some patients completed the instrument only at 6 months
(n=10) or 12 months (n=10). Therefore, we used both an observed cases approach (i.e., using
all assessments available) and an intention-to-treat (ITT) approach. In the more conservative
ITT analysis, we focused on the 12 month assessment. If a 12 month assessment was not
available, we used the last observation (i.e., 6 months) carried forward. Because both methods
provided similar results, we report the ITT analysis. Repeated measures analysis of variance
(ANOVA) was used to test whether mean scores changed statistically from baseline to follow-
up. Post hoc analyses using Duncan’s multiple range test were conducted to explore group
differences for variables deemed to be significant (P<0.05) in the repeated measures ANOVA.
SAS (version 9.1.2, Cary, NC) was used for statistical analyses.
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Seventy-nine patients seen in the CKD clinic from January 2003 to September 2004 provided
baseline KDQOL-SF™ data (Table 2). More than 50 percent of patients were female. The
mean patient age was more than 60 years and nearly half of patients were African American.
The primary cause of kidney disease was either hypertension or diabetes mellitus. Of the 79
patients with a baseline KDQOL-SF™ assessment, 43 of these patients (54%) had at least one
follow-up KDQOL-SF™ assessment. A comparison of the baseline clinical characteristics
(Table 1) between patients with (n = 43) and without (n = 36) a follow-up KDQOL-SF™
assessment demonstrated that only serum calcium was significantly different between the
baseline only group and the follow-up group, respectively (8.6 ± 0.9 mg/dL versus 9.1 ± 0.5
mg/dL (p < 0.05)). For all other baseline characteristics, patients with followup measures did
not differ statistically from patients without KDQOL-SF™ followup measures.
Baseline quality of life scores were comparable for patients with only a baseline KDQOL™
assessment and patients who had at least one followup assessment (Table 3), with two
exceptions. Patients with followup KDQOL™ data had higher baseline quality of life scores
than patients without followup data on two kidney disease-targeted scales; effect of kidney
disease (mean 78.6 vs. 68.8, respectively, (p < 0.05)) and burden of kidney disease (mean 72.8
vs. 66.6, respectively (p < 0.05)). The 36-item health survey scale scores and overall health
status (physical and mental component) were similar between patients with only a baseline and
those with at least one follow-up assessment (p > 0.05)
Compared to two larger cohorts,23,24 mean scores on the kidney disease specific scales from
the KDQOL-SF™ showed a trend toward higher values for patients in the CKD clinic (Figure
1). Although we did not have access to estimates of variance to make statistical comparisons
of the means from our population with means from the US dialysis population,23 we did have
confidence bounds for a study in Canadian dialysis patients.24 Comparing these groups, our
CKD population had significantly higher ratings on the domains for “effects of kidney disease”
and “burden of kidney disease”. This is illustrated by the non-overlapping 95% confidence
intervals for these domains in Figure 1.
A plot of the mean scores for the SF-36 component (overall health status) domains from our
study and three additional studies was also evaluated (Figure 2). These data showed that
compared to the general US population,26 patients with kidney disease have lower general
QOL values – as seen in our CKD study, the RRI-CKD study,25 and the DOPPS ESRD study
(Figure 2).23 Mean domain specific estimates from our CKD population appeared lower than
the previously reported CKD estimates from the Perlman, et al study.25 However, our
population was smaller and had wider confidence intervals. Our confidence intervals
overlapped with the previous CKD study in all domains except social functioning, whereby
our mean score was lower. Patients in our CKD clinic had similar general health domain scores
as compared to estimates from patients with ESRD on hemodialysis, with the exception of
physical functioning which was greater in our CKD population. The mean results from the
general health domains between populations were not tested statistically since the raw data
from the comparative studies were not available.
In exploring whether certain demographic and clinical characteristics impacted baseline
assessment of the 9 kidney disease specific domains of the KDQOL-SF™, we found a
borderline significant effect of hemoglobin (p=0.06). Work status (p = 0.02), cognitive function
(p = 0.06),and quality of social interaction (p = 0.08) were identified as contributing factors to
the significant overall effect of hemoglobin (data not shown).
A comparison of the change in kidney disease specific and general health domains of the
KDQOL-SF™ was made from baseline to follow-up in our patients who completed a follow-
Hansen et al. Page 5













up survey (n = 43). In general, quality of life scales showed numerical improvement at followup
in our CKD population (Table 4). Statistically significant improvements (p < 0.05) were
observed with regard to sleep (change of 6.2 ± 15.2) and social function (change of 11.6 ±
27.7). The social support and physical function scales showed slight numerical declines,
although changes were not statistically significant.
DISCUSSION
A previous publication highlighting our multidisciplinary clinic demonstrated the feasibility
and clinical effectiveness of a model to deliver anemia management to patients with CKD. In
the clinic model, the target hemoglobin (11 to 12 g/dL) for erythropoietic stimulating agent
treatment was based on guidelines endorsed by the National Kidney Foundation. 27 In this
manuscript, we provide baseline and follow-up estimates of quality of life (as measured by the
KDQOL-SF™) for a cohort of our clinic patients with CKD receiving anemia management
with erythropoietic proteins. Overall, our kidney disease specific estimates (as assessed by the
kidney disease components in the KDQOL™) demonstrated better quality of life as compared
to patients with ESRD.23,24 Our baseline measures of kidney disease specific quality of life
are useful as a benchmark in CKD patients. This benchmark is useful to help gauge the
effectiveness of anemia interventions and to put the negative effects of CKD into perspective.
Our baseline measures suggest that CKD is especially detrimental with regard to ability to
work (i.e., work status = 31.7) and role limitations caused by physical health problems (i.e.,
role-physical = 39.0).
Because the KDQOL-SF™ is designed specifically for kidney disease, quality of life measured
on this scale cannot be compared to a healthy population. However, the SF-36 – a generic
measure of health status – has been used as a measure of quality of life in healthy populations.
26 Compared to healthy populations, patients with pre-dialysis CKD demonstrated significantly
lower health status scores on the SF-36 – as shown in Figure 2. Compared to populations with
ESRD,23, 24 patients with pre-dialysis CKD had similar health status. This finding of similar
QOL score for general health domains, as measured by the SF-36 for CKD and ESRD patients,
suggests that the SF-36 may not be sensitive enough to detect kidney disease stage specific
measures of QOL. Our data also suggested this - showing a trend toward disparate scores in
several measures of the kidney disease specific questions of the KDQOL-SF™ between CKD
and ESRD and a lack of disparate scores in similar domains of the SF-36 component between
these groups. The implications of this observation may be that specific reductions in QOL
attributed to kidney disease will be overlooked in the SF-36. Hence, centers that use this latter
measure only may not have the sensitivity to find true reductions in QOL in the CKD patient
population. Additionally, as patients move from one stage of CKD to another, it may not be
practical to detect QOL changes that may be apparent from less severe to more severe disease
staging. Therefore, the impact of stage of kidney disease on QOL may best be assessed by the
kidney specific component of the KDQOL-SF™. Further validation of this assertion is needed
since the KDQOL-SF™ has not previously been validated in CKD, even though it has been
used in previous studies of CKD.15, 16
In the subset of our patients who provided longitudinal assessments of quality of life, we found
general trends towards improvement in quality of life while enrolled in the CKD clinic. With
regard to the kidney disease specific domains, improvements in QOL were statistically
significant with regard to sleep and social functioning. It is difficult to expand on why these
factors improved, and future work should consider further exploration of this area. We did not
see any statistically significant improvements (only trends in improvements) in the general
health domains of the KDQOL-SF™. We also did not assess changes in KDQOL-SF™ scores
in relationship to changes in CKD stage since our follow-up time period was ≤ one year in
duration. A study that tested KDQOL™ in a longitudinal approach from CKD to ESRD showed
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that patients who transitioned to dialysis had significant decreases in the domain scores for
burden and effects of kidney disease.28 This suggests that changes in kidney function may
obscure clinical and QOL improvements that result from other interventions such as
management of anemia.
The slightly lower reported general SF-36 scores in our population versus the previous
publication needs to be explored. There are at least two possible explanations for this
observation. The first being differences in the racial make-up of the two studies. Our study had
∼50% African-Americans and the previous CKD study had ∼25% of patients in this race
category.25 While it has been reported in hemodialysis patients that African-American patients
report higher QOL scores in most domains,29 one needs to consider the effect of changes in
kidney function (consistent with the CKD process) and its effect on QOL. Hence, the second
factor is the effect of changes in kidney function (i.e. changes in CKD staging). Declines in
kidney function may occur at different rates in different racial backgrounds and hence may
effect QOL self-reports. 28 If patients were evaluated in a relative state of a more rapid decline,
it is reasonable to entertain the prospect that this may result in a lower reported QOL value
across many domains. This would potentially reduce the positive impact that race may have
had on QOL score (as in an African-American population). We did not assess changes in kidney
function over time to enable an assessment in this regard. Additionally, trends in follow-up
QOL values in the Perlman, et al study were not reported.25
Although not an initial aim of our study, we retrospectively evaluated patient demographic and
clinical parameters to assess their impact on predicting baseline QOL. While most clinical
measures (calcium, phosphorus, parathyroid hormone, glomerular filtration rate, serum
creatinine, transferrin saturation, and ferritin) did not appear to have a significant effect on
QOL, their contribution cannot be ruled out since our study was not adequately powered for
this analysis. Hemoglobin trended towards significance (i.e., P = 0.06) as a predictor of kidney
specific domains. Since previous studies have reported that anemia – assessed by low
hemoglobin – is related to lower quality of life,25,30 we hypothesize that untreated baseline
anemia is a contributing factor to the low QOL estimates we found in the CKD clinic. Our
mean ± standard deviation follow-up hemoglobin values for these patients (11.7 ± 0.7) 11 were
within the planned target range and are consistent with the currently recommended range by
the Food and Drug Administration for patients receiving erythropoiesis stimulating agents.13
A recent CKD study showed QOL values in low (11.5 g/dL) and high (13.5 g/dL) hemoglobin
arms to be relatively consistent after therapy with erythropoietin beta for two years.12 Hence
correction of hemoglobin levels to within the acceptable range appears to provide similar scores
for QOL without enhanced risk for cardiovascular complications.12,31 Although we did not
have sufficient statistical power to actually test whether longitudinal improvements in
hemoglobin were correlated with improvements in quality of life, this presents an opportunity
for future research.
Our study has several other limitations that need to be considered. First and foremost, it was
observational in nature and was not powered to detect statistically significant changes. Future
studies should use our preliminary effect size estimates to conduct a randomized, controlled
study to test (a priori) the factors, such as hemoglobin and/or changes in CKD staging, that
may predict improved quality of life. The baseline estimates of quality of life are limited by
our relatively small convenience sample. Patients were not randomly selected, but rather were
eligible due to their participation in our CKD clinic and their willingness to complete quality
of life surveys. Furthermore, our study population was derived from one clinical site. We
conducted hypothesis tests among a subset of patients that had endpoint assessments to
determine whether quality of life changed over time; these tests should be interpreted in light
of the fact that our study was not designed to test hypotheses. Multivariate analysis should be
viewed strictly as exploratory given the small sample size. Sample size also limited our ability
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to make stage-specific inferences. Still, this study provides insight for a pre-dialysis CKD
population that has not been well studied in terms of QOL assessments by the KDQOL-SF™.
CONCLUSIONS
Patients with kidney disease have significantly decreased quality of life compared to healthy
populations as assessed by the SF-36. QOL measures that assess effect of kidney disease, such
as the KDQOL-SF™, may be most useful to detect changes in QOL associated with progression
of kidney disease. Patient reported improvements in QOL can be realized in a multidisciplinary
CKD clinic that incorporates management of anemia to an accepted target range.
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Figure 1. Comparison of kidney disease specific scales chronic kidney disease populations
 CKD Clinic (n=79)
 US dialysis patients 23 (n=2,885)a
 Canadian dialysis patients 24 (n=192)
a 95% confidence intervals not available for this study
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Figure 2. Comparison of SF-36 domains for pre-dialysis chronic kidney disease, end-stage kidney
disease, and the general US population
 CKD Clinic (n=79)
 RRI-CKD Study 25 (n=505)
 US Dialysis Patients 23 (n=2,885)
 US Population Average 26 (n=192)
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Table 1
Chronic kidney disease staging and projected prevalence
CKD Stage Stage Definition
Projected prevalence in US population a
(N) (%)
1 Kidney damage with GFR ≥ 90 5,900,000 3.3
2 Kidney damage with GFR 60–89 5,300,000 3.0
3 GFR 30–59 7,600,000 4.3
4 GFR 15–29 400,000 0.2
5 GFR < 15 300,000 0.1
CKD – chronic kidney disease
GFR (ml/min/1.73m2) – glomerular filtration rate
a
Number and percentage based on estimates from the National Kidney Foundation2
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Table 2
Baseline patient characteristics










n (%) n (%) n (%)
Sex
  Male 37 (47%) 19 (53%) 18 (42%)
  Female 42 (53%) 17 (47%) 25 (58%)
Race
  Caucasian 40 (51%) 19 (53%) 21 (49%)
  African American 37 (47%) 17 (47%) 20 (46%)
  Other 2 (2%) 0 (0%) 2 (5%)
Cause of kidney disease
  Hypertension 30 (38%) 15 (41.7%) 15 (35%)
  Diabetes Mellitus 28 (35%) 12 (33.3%) 16 (37%)
  Other 39 (49%) 22 (61%) 17 (40%)
  Unknown 1 (1.3%) 1 (2.8%) 0 (0%)
mean ± sd mean ± sd mean ± sd
Age (years) 62.2 ± 15.3 59.4 ± 17.3 64.6 ± 13.1
Hb (g/L) 11.0 ± 1.4 11.1 ± 1.5 10.9 ± 1.4
TSAT (%) 25.9 ± 14.5 26.9 ± 16.5 25.1 ± 12.7
Ferritin (mcg/L) 180.3 ± 156.3 161.4 ± 132.1 196.0 ± 173.8
iPTH (pg/mL) 190.4 ± 180.7 233.4 ± 241.0 158.6 ± 111.4
Calcium (mg/dL) 8.9 ± 0.8 8.6 ± 0.9 9.1 ± 0.5a
PO4 (mg/dL) 4.2 ± 1.1 4.2 ± 1.1 4.2 ± 1.1
Creatinine (mg/dL) 3.1 ± 1.4 3.2 ± 1.5 3.0 ± 1.4
Hb – Hemoglobin; g – grams; L – Liter; TSAT – transferring saturation; mcg – micrograms; iPTH – intact parathyroid hormone; pg - picograms; mL –
milliliter; mg – milligram; dL – deciliter; PO4 - phosphate
a
P < 0.05 for comparing baseline scores for patients with a baseline measure and at least one endpoint assessment to patients with only a baseline measure;
calcium is not adjusted for albumin.
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Table 3











mean (sd) mean (sd) mean (sd)
Kidney disease-targeted scales
  Symptom/problems 73.4 (15.6) 70.4 (15.9) 76.0 (15.3)
  Effects of kidney disease b 74.1 (22.7) 68.8 (23.0) 78.6 (22.2)
  Burden of kidney disease b 66.6 (29.9) 59.4 (31.6) 72.8 (27.2)
  Work status 33.1 (41.8) 34.7 (44.4) 31.7 (39.9)
  Cognitive function 80.0 (21.3) 77.6 (21.2) 82.1 (21.6)
  Quality of social interaction 75.0 (20.3) 73.3 (20.0) 76.4 (20.7)
  Sexual function 81.9 (26.4) 81.7 (30.9) 88.5 (21.1)
  Sleep 56.8 (18.2) 56.1 (17.7) 57.3 (18.8)
  Social support 76.1 (26.5) 72.9 (25.3) 78.7 (27.5)
36-Item health survey scales
  Physical functioning 49.8 (29.2) 46.6 (28.9) 52.5 (29.6)
  Role-physical 39.3 (43.2) 39.7 (44.0) 39.0 (43.1)
  Pain 63.2 (26.5) 62.6 (25.6) 63.7 (27.6)
  General health perceptions 42.3 (22.2) 41.5 (23.8) 42.9 (21.0)
  Emotional well-being 68.7 (23.1) 63.7 (22.5) 72.9 (23.1)
  Role-emotional 57.5 (44.8) 54.9 (45.6) 59.5 (44.5)
  Social function 60.0 (28.0) 56.6 (29.2) 62.8 (26.9)
  Energy/fatigue 40.4 (24.9) 34.6 (22.3) 45.4 (26.2)
Overall health status
  SF-36 Physical Composite 35.7 (11.7) 35.9 (11.8) 35.5 (11.8)
  SF-36 Mental Composite 46.0 (13.2) 43.5 (13.0) 48.1 (13.2)
a
All scales have a possible range of 0–100, with higher transformed scores always reflecting better quality of life
b
P < 0.05 for t-test comparing mean baseline scores for patients with a baseline measure and at least one endpoint assessment to patients with only a
baseline measure
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Table 4
Baseline, follow-up, and mean change values a on the KDQOL-SF™ (n=43)
Measure Patients (n=43) with a baseline measure and at least one follow-up measure (ITT)
Baseline Follow-up Change
mean (sd) mean (sd) mean (sd)
Kidney disease-targeted scales
  Symptom/problems 76.0 (15.3) 77.0 (16.1) 1.0 (12.2)
  Effects of kidney disease 78.6 (22.2) 80.5 (18.3) 1.4 (17.8)
  Burden of kidney disease 72.8 (27.2) 74.5 (25.2) 0.9 (24.8)
  Work status 31.7 (39.9) 34.1 (42.5) 3.8 (31.2)
  Cognitive function 82.1 (21.6) 84.7 (15.6) 2.6 (20.5)
  Quality of social interaction 76.4 (20.7) 81.6 (15.6) 5.2 (20.9)
  Sexual function 88.5 (21.1) 89.8 (17.4) 0.3 (16.5)
  Sleep b 57.3 (18.8) 63.4 (16.7) 6.2 (15.2)
  Social support 78.7 (27.5) 77.8 (34.7) –0.4 (43.2)
36-Item health survey scales
  Physical functioning 52.5 (29.6) 51.7 (28.9) –0.5 (19.3)
  Role-physical 39.0 (43.1) 44.4 (43.2) 5.8 (36.3)
  Pain 63.7 (27.6) 67.0 (24.1) 2.6 (21.4)
  General health perceptions 42.9 (21.0) 43.8 (18.9) 0.9 (14.0)
  Emotional well-being 72.9 (23.1) 77.1 (13.8) 4.5 (18.8)
  Role-emotional 59.5 (44.5) 61.0 (42.1) 0.8 (28.7)
  Social function b 62.8 (26.9) 74.4 (24.8) 11.6 (27.7)
  Energy/fatigue 45.4 (26.2) 46.1 (22.8) 1.3 (20.9)
Overall health status
  SF-36 Physical Composite 35.5 (11.8) 35.6 (11.1) 0.2 (8.5)
  SF-36 Mental Composite 48.1 (13.2) 50.3 (9.4) 2.0 (10.1)
a
All scales have a possible range of 0–100, with higher transformed scores always reflecting better quality of life
b
P < 0.005 for repeated measures F-statistic.
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